Enzymes approved for human therapy: Indications, mechanisms and adverse effects

BioDrugs

Volumn 29, Issue 1, 2015, Pages 31-55

  Baldo, Brian A ^a  

^a NONE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALTEPLASE; ASPARAGINASE; CARBOXYPEPTIDASE G2; COLLAGENASE; DORNASE ALFA; ELOSULFASE ALFA; GALSULFASE; IDURONATE 2 SULFATASE; IMIGLUCERASE; LARONIDASE; METHOTREXATE; OCRIPLASMIN; PEGADEMASE; PEGLOTICASE; RASBURICASE; RECOMBINANT ENZYME; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; RETEPLASE; TALIGLUCERASE ALFA; TENECTEPLASE; VELAGLUCERASE ALFA; ENZYME;

ABDOMINAL PAIN; ACUTE PANCREATITIS; AFFERENT PUPILLARY DEFECT; AIRWAY OBSTRUCTION; ALLERGIC REACTION; ALLERGY; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIBODY RESPONSE; ANXIETY; APNEA; ARTHRALGIA; ASTHMA; AUTOIMMUNE HEMOLYTIC ANEMIA; BACKACHE; BLOOD CLOTTING DISORDER; BLURRED VISION; BONE PAIN; BRAIN DYSFUNCTION; BRAIN HEMORRHAGE; BRAIN INFARCTION; BURNING SENSATION; CARDIOPULMONARY INSUFFICIENCY; CEREBROVASCULAR ACCIDENT; CHILL; CHRONIC DISEASE; COLOR VISION DEFECT; CONGESTIVE HEART FAILURE; CONJUNCTIVAL HEMORRHAGE; CONSTIPATION; CONTUSION; COUGHING; CYSTIC FIBROSIS; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOXICITY; DUPUYTREN CONTRACTURE; DYSPEPSIA; DYSPNEA; ECCHYMOSIS; EDEMA; ELEVATED BLOOD PRESSURE; EMPYEMA; ENZYME ISOLATION; ENZYME REPLACEMENT; EPISTAXIS; ERECTILE DYSFUNCTION; ERYTHEMA; EYE PAIN; FABRY DISEASE; FATIGUE; FEVER; FLUSHING; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GAUCHER DISEASE; GENITAL PRURITUS; GLYCOGEN STORAGE DISEASE TYPE 2; GOUT; HEADACHE; HEART INFARCTION; HEART PALPITATION; HEMOLYSIS; HEMOLYTIC ANEMIA; HEMOPTYSIS; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERHIDROSIS; HYPERSENSITIVITY; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOTENSION; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNE DYSREGULATION; IMMUNOGENICITY; INFUSION RELATED REACTION; INJECTION SITE PAIN; INJECTION SITE REACTION; INTRAOCULAR HYPERTENSION; KETOACIDOSIS; LARYNGITIS; LEUKEMIA; LIMB PAIN; LIVER TOXICITY; LUNG DISEASE; LYSOSOME STORAGE DISEASE; MAROTEAUX LAMY SYNDROME; METHEMOGLOBINEMIA; MORQUIO SYNDROME; MUCOPOLYSACCHARIDOSES 4A; NAUSEA; NAUSEA AND VOMITING; OTALGIA; PAIN; PANCREATITIS; PAPILLEDEMA; PARESTHESIA; PENILE SWELLING; PERIPHERAL EDEMA; PHARYNGITIS; PLEURA EFFUSION; PNEUMONIA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PRURITUS; RASH; RESPIRATORY DISTRESS; RETINA DETACHMENT; RETINA EDEMA; RETINA MACULA HOLE; RETINA TEAR; REVIEW; RHINITIS; RHINOPHARYNGITIS; SEPSIS; SEVERE COMBINED IMMUNODEFICIENCY; SIDE EFFECT; SKIN ALLERGY; SKIN TINGLING; SUBDURAL HEMATOMA; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOSIS; TONGUE SWELLING; TREMOR; TUMOR LYSIS SYNDROME; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VASCULITIS; VEIN THROMBOSIS; VIRUS INFECTION; VISUAL DISORDER; VISUAL IMPAIRMENT; VITREOUS BODY DETACHMENT; VITREOUS FLOATERS; VOMITING; ADVERSE EFFECTS; ANIMAL; PROCEDURES; RARE DISEASES;

ANIMALS; ENZYME REPLACEMENT THERAPY; ENZYMES; HUMANS; RARE DISEASES;

EID: 84922643812     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-015-0116-7     Document Type: Review

References (219)

1. Beutler E. Enzyme replacement therapy. TIBS. 1981;6:95-6.
2. Neufeld EF. Enzyme replacement therapy - a brief history. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: Perspectives from 5 years of FOS. Oxford: Oxford Pharmagenesis; 2006. Ch 10.
3. Frantanoni JC, Hall CW, Neufeld EF. The defect in Hurler's and Hunter's syndromes: faulty degradation of mucopolysaccharide. Proc Natl Acad Sci USA. 1968;60:699-706.
4. Hickman S, Neufeld EF. A hypothesis for I-cell disease: defective hydrolases that do not enterlysosomes. Biochem Biophys Res Commun. 1972;49:992-9.
5. Kaplan A, Achord DT, Sly WS. Phosphohexosyl components of a lysosomal enzyme are recognized by pinocytosis receptors on human fibroblasts. Proc Natl Acad Sci USA. 1977;74:2026-30.
6. Kaplan A, Fischer D, Achord DT, Sly WS. Phosphohexosyl recognition is a general characteristic of pinocytosis of lysosomal glycosidases by human fibroblasts. J Clin Invest. 1977;60:1088-93.
7. Ullrich K, Mersmann G, Weber E, et al. Evidence for lysosomal enzyme recognition by human fibroblasts via a phosphorylated carbohydrate moiety. Biochem J. 1978;170:643-50.
8. Hasilik A, Neufeld EF. Biosynthesis of lysosomal enzymes in fibroblasts. Phosphorylation of mannose residues. J Biol Chem. 1980;255:4946-50.
9. Varki A, Kornfeld S. Structural studies of phosphorylated high mannose-type oligosaccharides. J Biol Chem. 1980;255:10847-58.
10. Achord DT, Brot FE, Sly WS. Inhibition of the rat clearance system for agalacto-orosomucoid by yeast mannans and by mannose. Biochem Biophys Res Commun. 1977;77:409-15.
11. Achord DT, Brot FE, Bell CE, et al. Human β-glucuronidase: in vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells. Cell. 1978;15:269-78.
12. Schlesinger PH, Doebber TW, Mandell BF, et al. Plasma clearance of glycoproteins with terminal mannose and N-acetylglucosamine by liver non-parenchymal cells. Studies with β-glucuronidase, N-acetyl- β-d -glucosaminidase, ribonuclease B and agalacto-orosomucoid. Biochem J. 1978;176:103-9.
13. Stahl PD, Rodman JS, Miller MJ, et al. Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages. Proc Natl Acad Sci USA. 1978;75:1399-403.
14. Pontow SE, Kery V, Stahl PD. Mannose receptor. Int Rev Cytol. 1992;137B:221-44.
15. Grabowski GA, Petsko GA, Kolodny EH. Gaucher disease. http://www.ommbid.com/OMMBID/the-online-metabolic-and-molecular-bases-of-inherited-disease/b/abstract/part16/ch146. Accessed 11 Sept 2014.
16. Meikle PJ, Hopwood JJ, Clague AE, et al. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249-54.
17. Barton NW, Furbish FS, Murray GJ, et al. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA. 1990;87:1913-6.
18. Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher disease. N Engl J Med. 1991;324:1464-70.
19. Furbish FS, Steer CJ, Krett NL, et al. Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochim Biophys Acta. 1981;673:425-34.
20. Shar RR. Regulatory framework for the treatment of orphan diseases. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: Perspectives from 5 years of FOS. Oxford: Oxford Pharmagenesis; 2006. Ch 11.
21. FDA. For Industry. Developing products for rare diseases and conditions. http://www.fda.gov/forindustry/DevelopingProductsforrareDiseasesConditions/default.htm. Accessed 11 Sept 2014.
22. FDA. CDER Therapeutic Biologic Products. CDER billable biologic product list. http://www.fda.gov/drugs/developmentapprovalprocess/druginnovation/default.htm. Accessed 11 Sept 2014.
23. Deegan PB, Cox TM. Imiglucerase in the treatment of Gaucher disease: a history and perspective. Drug Des Devel Ther. 2012;6:81-106.
24. Cerezyme® (imiglucerase). http://www.cerezyme.com/~/media/CerezymeUS/Files/pdf/cerezyme-pi.pdf Accessed 11 Sept 2014.
25. Elelyso® (taliglucerase alfa). FDA clinical review. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2012/022458Orig1s000MedR.pdf. Accessed 11 Sept 2014.
26. Zimran A, Brill-Almon E, Chertkoff R, et al. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood. 2011;118:5767-73.
27. Hollak CEM. An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease. Core Evid. 2012;7:15-20.
28. VPRIV® (velaglucerase alfa). FDA clinical review. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2010/022575s000medr.pdf. Accessed 11 Sept 2014.
29. Aerts JMFG, Yasothan U, Kirkpatrick P. Velaglucerase alfa. Nat Rev Drug Discov. 2010;9:837-8.
30. Turkia HB, Gonzalez DE, Barton NW, et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. Am J Hematol. 2013;88:179-84.
31. Shaaltiel Y, Bartfeld D, Hashmueli S, et al. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol J. 2007;5:579-90.
32. Brumshtein B, Salinas P, Peterson B, et al. Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages. Glycobiology. 2010;20:24-32.
33. Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford Pharmagenesis; 2006.
34. Ioannou YA, Bishop DF, Desnick RJ. Overexpression of human alpha-galactosidase A results in its intracellular aggregation, crystallization in lysosomes, and selective secretion. J Cell Biol. 1992;11:1137-50.
35. Ohshima T, Murray GJ, Swaim WD, et al. Alpha-galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci USA. 1997;94:2540-4.
36. Ioannou YA, Zeidner KM, Gordon RE, et al. Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am J Human Genet. 2001;68:14-25.
37. Replagal® (agalsidase alfa). EMA Scientific discussion. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/human/000369/WC500053608.pdf. Accessed 11 Sept 2014.
38. Fabrazyme® (agalsidase beta) http://www.accessdata.fda.gov/drugsatfda-docs/label/2003/agalgen042403LB.pdf. Accessed 11 Sept 2014.
39. Lee K, Jin X, Zhang K, et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology. 2003;13:305-13.
40. Sakuraba H, Murata-Ohsawa M, Kawashima I, et al. Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. J Hum Genet. 2006;51:180-8.
41. Vedder AC, Linthorst GE, Houge G, et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS One. 2007;2(7):e598.
42. van der Ploeg AT, Reuser AJJ. Lysosomal storage disease 2. Pompe's disease. Lancet. 2008;372:1342-63.
43. Van Hove JL, Yang HW, Wu JY, et al. High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease. Proc Natl Acad Sci USA. 1996;93:65-70.
44. Bijvoet AG, Kroos MA, Pieper FR, et al. Recombinant human acid alpha-glucosidase: high-level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice. Hum Mol Genet. 1998;7:1815-24.
45. Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007;68:99-109.
46. Zhao K-W, Faull KF, Kakkis ED, et al. Carbohydrate structure of recombinant human α-l-iduronidase secreted by Chinese hamster ovary cells. J Biol Chem. 1997;272:22758-65.
47. Brooks DA, Fabrega S, Hein LK, et al. Glucosidase active site mutations in human α-l-iduronidase. Glycobiology. 2001;11:741-50.
48. Jameson E, Jones S, Wraith JE. Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I. Cochrane Database Syst Rev. 2013;9:CD009354. doi: 10.1002/14651858.CD009354.pub2.
49. Burrow TA, Leslie ND. Review of the use of idursulfase in the treatment of mucopolysaccharidosis II. Biol Targets Ther. 2008;2:311-20.
50. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The metabolic and molecular basis of inherited disease. 8th ed. New York: McGraw-Hill; 2001. p. 3421-52.
51. Wilson PJ, Morris CP, Anson DS, et al. Hunter syndrome: isolation of an iduronidat-2-sulfatase cDNA clone and an analysis of patient DNA. Proc Natl Acad Sci USA. 1990;87:8531-5.
52. Tomatsu S, Montano AM, Gutierrez M, et al. Characterization and pharmacokinetic study of recombinant human N-acetylgalactosamine-6-sulfate sulfatase. Mol Genet Metab. 2007;91:69-78.
53. Vimizim® (elosulfase alfa). FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/125460s000lbl.pdf. Accessed 12 Sept 2014.
54. EMA: Assessment report. Vimizim® (elosulfase alfa). http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002779/WC500169242.pdf. Accessed 12 Sept 2014.
55. Tomatsu S, Montano AM, Oikawa H, et al. Mucopolysaccharidosis type IVA (Morquio disease): clinical review and current treatment. Curr Pharm Biotechnol. 2011;12:931-45.
56. Hopwood JJ, Bate G, Kirkpatrick P. Galsulfase. Nat Rev Drug Discov. 2006;5:101-2.
57. Valayannopoulos V, Nicely H, Harmatz P, et al. Mucopolysaccharidosis VI. Orphanet J Rare Dis. 2010;5:5. doi: 10.1186/1750-1172-5-5.
58. LourenÒo CM, Giugliani R. Evaluation of galsulfase for the treatment of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Expert Opin Orphan Drugs. 2014;2:407-17.
59. Pennica D, Holmes WE, Kohr WJ, et al. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature. 1983;301:214-21.
60. Ny T, Elgh F, Lund B. The structure of the human tissue-type plasminogen activator gene: correlation of intron and exon structures to function and structural domains. Proc Natl Acad Sci USA. 1984;81:5355-9.
61. Collen D, Lijnen HR. The tissue-type plasminogen activator story. Arterioscler Throm Vasc Biol. 2009;29:1151-5.
62. Cartwright T. Production of t-PA from animal cell culture. In: Spier RE, Griffiths JB, editors. Animan cell biotechnology, vol. 5. London: Academic Press; 1992. p. 217-45.
63. Sarmientos P, Duchesne M, Denéfle P, et al. Synthesis and purification of active human tissue plasminogen activator from Escherichia coli. Nat Biotechnol. 1989;7:495-501.
64. Datar RV, Cartwright T, Rosen C-G. Process economics of animal cell and bacteria fermentations: a case study analysis of tissue plasminogen activator. Biotechnology. 1993;11:349-57.
65. Longstaff C, Williams S, Thelwell C. Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008;6:212-23.
66. Manosroi J, Tayapiwatana C, Gotz F, et al. Secretion of active recombinant human tissue plasminogen activator derivatives in Escherichia coli. Appl Environ Microbiol. 2001;67:2657-64.
67. Melandri G, Vagnarelli F, Calabrese D, et al. Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vasc Health Risk Manag. 2009;5:249-56.
68. Pieters R, Appel I, Kuehnel HJ, et al. Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial. Blood. 2008;112:4832-8.
69. Broome JD. Evidence that the l-asparaginase of guinea pig serum is responsible for its antilymphoma effects. Nature. 1961;191:1114-5.
70. Rytting ME. Role of l-asparaginase in acute lymphoblastic leukemia: focus on adult patients. Blood Lymphat Cancer Targets Ther. 2012;2:117-24.
71. Wetzler M, Sanford BL, Kurtzberg J, et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood. 2007;109:4164-7.
72. Xiaflex® (collagenase clostridium histolyticum). FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/125338lbl.pdf. Accessed 12 Sept 2014.
73. Xiapex®. EMA: Summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002048/WC500103373.pdf. Accessed 12 Sept 2014.
74. Matsushita O, Okabe A. Clostridial hydrolytic enzymes degrading extracellular components. Toxicon. 2001;39:1769-80.
75. Mookhtiar KA, Van Wart HE. Clostridium histolyticum collagenases: a new look at some old enzymes. Matrix Suppl. 1992;1:116-26.
76. Edkins TJ, Koller-Eichhorn R, Alhadeff JA, et al. Assessment of potential cross-reactivity of human endogenous matrix metalloproteinases with collagenase Clostridium histolyticum antibodies in human serum obtained from patients with Dupuytren's contracture. Clin Vaccine Immunol. 2012;19:562-9.
77. Shak S, Capon DJ, Hellmiss R, et al. Recombinant human Dnase I reduces the viscosity of cystic fibosis sputum. Proc Natl Acad Sci USA. 1990;87:9188-92.
78. Picot R, Das I, Reid L. Pus, deoxyribonucleic acid and sputum viscosity. Thorax. 1978;33:235-42.
79. Nasr SZ, Strouse PJ, Soskolne E, et al. Efficacy of recombinant human deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis. Chest. 2001;120:203-8.
80. Hendriks T, de Hoog M, Lequin MH, et al. Dnase and atelectasis in non-cystic fibrosis pediatric patients. Crit Care. 2005;9:R351-6.
81. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994;331:637-42.
82. McCoy K, Hamilton S, Johnson C, The Pulmozyme Study Group. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Chest. 1996;110:889-95.
83. Fitzgerald DA, Hilton J, Jepson B, et al. A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis. Pediatrics. 2005;116:e549-54.
84. Sherwood RF, Melton RG, Alwan SM, et al. Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method. Eur J Biochem. 1985;148:447-53.
85. Green JM. Glucarpidase to combat toxic levels of methotrexate in patients. Ther Clin Risk Manag. 2012;8:403-13.
86. Hempel G, Lingg R, Boos J. Interactions of carboxypeptidase G(2) with 6S-leucovorin and 6R-leucovorin in vitro: implications for the application in case of methotrexate intoxications. Cancer Chemother Pharmacol. 2005;55:347-53.
87. Nagai N, Demarsin E, Van Hoef B, et al. Recombinant human microplasmin: production and potential therapeutic properties. J Thromb Haemost. 2003;1:307-13.
88. Aerts F, Noppen B, Fonteyn L, et al. Mechanism of inactivation of ocriplasmin in porcine vitreous. Biophys Chem. 2012;165-166:30-8.
89. Stalmans P, Benz MS, Gandorfer A, et al. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction with macular holes. N Engl J Med. 2012;367:606-15.
90. Mitchell MD, Miller DM. Looking at ocriplasmin as a new option in eye disease. Drugs Today. 2012;48:519-24.
91. Syed YY, Dhillon S. Ocriplasmin: a review of its use in patients with symptomatic vitreomacular adhesion. Drugs. 2013;73:1617-25.
92. Adagen® (pegademase bovine). http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/019818s042lbl.pdf. Accessed 13 Sept 2014.
93. Adagen® (pegademase bovine). Product monograph. Sigma-Tau Pharmaceuticals Inc. http://www.adagen.com/pdf/Adagen-Monograph-Final.pdf. Accessed 13 Sept 2014.
94. Skonezny P. Process for preparing dideoxyinosine using adenosine deaminase enzyme. US Patent US20040175804, issued September 9, 2004.
95. Hershfield MS, Mitchell BS. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The metabolic and molecular basis of inherited disease. 7th ed. New York: McGraw-Hill; 1995. p. 1725-68.
96. Wong HK. Severe combined immunodeficiency. http://www.emedicine.com/derm/TOPIC879.HTM. Accessed 13 Sept 2014.
97. Puck JM. Neonatal screening for severe combined immunodeficiency. Curr Opin Allergy Clin Immunol. 2007;7:522-7.
98. Ea H-K, Richette P. Critical appraisal of the role of pegloticase in the management of gout. Open Access Rheumatol Res Rev. 2012;4:63-70.
99. Krystexxa® (pegloticase). EMA: CHMP assessment report. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002208/WC500138365.pdf. Accessed 13 Sept 2014.
100. Krystexxa® (pegloticase). FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/125293s034lbl.pdf. Accessed 13 Sept 2014.
101. Sundy JS, Baraf HSB, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment. Two randomized controlled trials. JAMA. 2011;306:711-20.
102. Bayol A, Capdevielle J, Malazzi P, et al. Modification of a reactive cysteine explains differences between rasburicase and Uricozyme, a natural Aspergillus flavus uricase. Biotechnol Appl Biochem. 2002;36:21-31.
103. Ho VQ, Wetzstein GA, Patterson SG, et al. Abbreviated rasburicase dosing for the prevention and treatment of hyperuricemia in adults at risk for tumor lysis syndrome. Support Cancer Ther. 2006;3:178-82.
104. Campara M, Shord SS, Haaf CM. Single-dose rasburicase for tumor lysis syndrome in adults: weight-based appreoach. J Clin Pharm Ther. 2009;34:207-13.
105. Kennedy LD, Ajiboye VO. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome. J Oncol Pharm Pract. 2010;16:205-13.
106. Howard SC, Jones DP, Pui C-H. The tumor lysis syndrome. N Engl J Med. 2011;364:1844-54.
107. Perry Wilson F, Berns JS. Onco-nephrology: tumor lysis syndrome. Clin J Am Soc Nephrol. 2012;7:1730-9.
108. Coiffier B, Mounier N, Bologna S, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) Study. J Clin Oncol. 2003;21:4402-6.
109. Schiffmann R, Kopp JB, Austim HA, et al. Enzyme replacement therapy in Fabry disease. A randomized controlled trial. JAMA. 2001;285:2743-9.
110. Australian public assessment report for agalsidase alfa ghu. https://www.tga.gov.au/pdf/auspar/auspar-replagal.pdf. Accessed 13 Sept 2014.
111. Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease. A randomized trial. Ann Intern Med. 2007;146:77-86.
112. Germain DP, Waldek S, Banikazemi M, et al. Sustained, long-term renal stabilization after 54 months of agalsidase β therapy in patients with Fabty disease. J Am Soc Nephrol. 2007;18:1547-57.
113. Schiffmann R, Ries M, Timmons M, et al. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant. 2006;21:345-54.
114. Lumizyme® (alglucosidase alfa). FDA: Highlights of prescribing information. http://www.lumizyme.com/~/media/LumizymeUS/Files/lumizyme-prescribing-information.pdf. Accessed 13 Sept 2014.
115. Myozyme® (alglucosidase alfa). FDA: highlights of prescribing information. http://www.myozyme.com/~/media/MyozymeUS/Files/Documents/mz-pi.pdf. Accessed 13 Sept 2014.
116. Myozyme® (alglucosidase alfa). EMA: summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000636/WC500032125.pdf. Accessed 13 Sept 2014.
117. van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med. 2010;362:1396-406.
118. Kishnani PS, Corzo D, Leslie ND, et al. Early treatment with alglucosidase alfa prolongs long-term survival of infants eith Pompe disease. Pediatr Res. 2009;66:329-35.
119. Cerezyme® (imiglucerase). http://www.cerezyme.com/~/media/CerezymeUS/Files/pdf/cerezyme-pi.pdf. Accessed 13 Sept 2014.
120. Starzyk K, Richards S, Yee J, et al. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genet Metab. 2007;90:157-63.
121. Kishnani PS, DiRocco M, Kaplan P, et al. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Mol Genet Metab. 2009;96:164-70.
122. Elelyso® (taliglucerase). FDA: highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/022458lbl.pdf. Accessed 13 Sept 2014.
123. van Dussen L, Zimran A, Akkerman EM, et al. Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. Blood Cells Mol Dis. 2013;50:206-11.
124. Morris JL. Velaglucerase alfa for the management of type 1 Guacher disease. Clin Ther. 2012;34:259-71.
125. Zimran A, Altarescu G, Philips M, et al. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Guacher disease: 48-month experience. Blood. 2010;115:4651-6.
126. Elstein D, Altarescu G, Maayan H, et al. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early access program results from Jerusalem. Blood Cells Mol Dis. 2012;48:45-50.
127. Wraith JE, Clarke LA, Beck M, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-l -iduronidase (laronidase). J Pediatr. 2004;144:581-8.
128. Aldurazyme® (laronidase). FDA: highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/125058s0186lbl.pdf. Accessed 15 Sept 2014.
129. Clarke LA, Wraith JE, Beck M, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatr. 2009;123:229-40.
130. Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006;8:465-73.
131. Muenzer J, Beck M, Eng CM, et al. Long-term, open-label extension study of idursulfase in the treatment of Hunter syndrome. Genet Med. 2011;13:95-101.
132. Okuyama T, Tanaka A, Suzuki Y, et al. Japan Elaprase Treatment (JET) study: Idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (mucopolysaccharidosis II, MPS II). Mol Genet Metab. 2010;99:18-25.
133. Burton BK, Whiteman DAH. On behalf of the HOS investigators. Incidence and timing of infusion reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS). Mol Genet Metab. 2011;103:113-20.
134. Eleprase® (idursulfase). FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/125151s0152lbl.pdf. Accessed 15 Sept 2014.
135. Elosulfase alfa. Canadian expert opinion. Recommendations for the use of elosulfase alfa in the management of MorquioA Syndrome (MPS IVA). June 16, 2014. http://www.garrod.ca/wp-content/uploads/Elosulfase-Canadian-Expert-Opinion.pdf. Accessed 15 Sept 2014.
136. Hendriksz CJ, Burton B, Fleming TR, et al. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis. 2014. doi: 10.1007/s10545-014-9715-6.
137. Vimizim® (elosulfase alfa). FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/125460s000lbl.pdf. Accessed 15 Sept 2014.
138. Naglazyme® (galsulfase). FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/125117s111lbl.pdf. Accessed 15 Sept 2014.
139. Galsulfase EMA. Scientific discussion. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/human/000640/WC500024285.pdf. Accessed 15 Sept 2014.
140. Harmatz P, Kramer WG, Hopwood JJ, et al. Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzymereplacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): a phase I/II study. Acta Paediatr Suppl. 2005;94:61-8.
141. Harmatz P, Ketteridge D, Giugliani R, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics. 2005;115:e681-9.
142. Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharid- osis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr. 2006;148:533-9.
143. Harmatz P, Giugliani R, Schwartz IV, et al. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab. 2008;94:469-75.
144. Horovitz DDG, Magalhães TSPC, Acosta A, et al. Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI. Mol Genet Metab. 2013;109:62-9.
145. Kim KH, Decker C, Burton BK. Successful management of difficult infusion-associated reactions in a young patient with mucopolysaccharidosis type VI receiving recombinant human arylsulfatase B (galsulfase [Naglazyme]). Pediatr. 2008;121:e714-7.
146. Doʇan M, Cesur Y, Peker E, et al. Thrombocytopenia associated with galsulfase treatment. Hum Exp Toxicil. 2011;30:768-71.
147. Koseoglu ST, Harmatz P, Turbeville S, et al. Reversed papilledema in an MPS VI patient with galsulfase (Naglazyme) therapy. Int Ophthalmol. 2009;29:267-9.
148. Califf RM, Topol EJ, George BS, et al. Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. Am J Med. 1988;85:353-9.
149. Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), phase II trial. Ann Intern Med. 1991;115:256-65.
150. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-82.
151. Topol EJ, Morris DC, Smalling RW, et al. A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (Activase) in acute myocardial infarction. J Am Coll Cardiol. 1987;9:1205-13.
152. Guerci AD, Gerstenblith G, Brinker JA, et al. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N Engl J Med. 1987;317:1613-8.
153. O'Rourke M, Baron D, Keogh A, et al. Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator. Circulation. 1988;77:1311-5.
154. Van de Werf F, Arnold AER, The European Cooperative Study Group for recombinant tissue type plasminogen activator. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. Brit Med J. 1988;297:1374-9.
155. Gore JM, Sloan M, Price TR, et al. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in myocardial infarction, phase II, pilot and clinical trial. Circulation. 1991;83:448-59.
156. Semba CP, Deitcher SR, Li X, The COOL Investigators, et al. Treatment of occluded central venous catheters with alteplase: results in 1064 patients. J Vasc Interv Radiol. 2002;2002(13):1199-205.
157. Thommi G, Nair CK, Aronow WS, et al. Efficacy and safety of intrapleural installation of alteplase in the management of complicated pleural effusion or empyema. Am J Ther. 2007;14:341-5.
158. Yayan J. Onset of orolingual angioedema after treatment of acute brain ischemia with alteplase depends on the site of brain ischemia: a meta-analysis. N Amer J Med Sci. 2013;5:589-93.
159. Hill MD, Lye T, Moss H, et al. Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke. Neurology. 2003;60:1525-7.
160. TM Activase® [Alteplase]. http://www.accessdata.fda.gov/drugsatfda-docs/label/2001/altegen090401lb.pdf. Accessed 11 Oct 2014.
161. Activase® (Alteplase, recombinant; recombinant tissue plasminogen activator, rt-PA) Cathflo® Activase® (Alteplase). Investigator brochure. Summary of changes September 19, 2013. http://braininjuryoutcomes.com/mistie-documents/finish/67/386. Accessed 11 Oct 2014.
162. Noble S, McTavish D. Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction. Drugs. 1996;52:589-605.
163. Simpson D, Siddiqui MA, Scott LJ, et al. Spotlight on reteplase in thrombotic occlusive disorders. BioDrugs. 2007;21:65-8.
164. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators. Circulation. 1996;94:891-8.
165. Van de Werf F, Cannon CP, Luyten A, et al. Safety assessment of a single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. Am Heart J. 1999;137:786-91.
166. Van de Werf F, Adgey J, Ardissino D, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Lancet. 1999;354:716-22.
167. Clinical review of reteplase. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm107736.pdf. Accessed 11 Oct 2014.
168. Rapilysin. Summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000105/WC500046734.pdf. Accessed 11 Oct 2014.
169. TM Tenecteplase recombinant. http://www.fda.gov/downloads/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/ucm200875.pdf. Accessed 11 Oct 2014.
170. Elspar® (asparaginase). FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/101063s5169lbl.pdf. Accessed 11 Oct 2014.
171. Cairo MS. Adverse reactions to l -asparaginase. Am J Pediatr Hematol Oncol. 1982;4:335-9.
172. Zakarija A, Kwaan HC. Adverse effects on hemostatic function of drugs used in hematologic malignancies. Semin Thromb Hemost. 2007;33:355-64.
173. Beinart G, Damon L. Thrombosis associated with l -asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia. Am J Hematol. 2004;77:331-5.
174. Larson RA, Fretzin MH, Dodge RK, et al. Hypersensitivity reactions to l -asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia. 1998;12:660-5.
175. Avramis VI, Sencer S, Periciou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002;99:1986-94.
176. Douer D, Aldoss I, Lunning MA, et al. Pharmacokinetics-based integration of multiple doses of intravenous pegasparaginase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia. J Clin Oncol. 2014;32:905-11.
177. Quintanilla-Flores DL, Flores-Caballero MA, Rodriguez-Gutierrez R, et al. Acute pancreatitis and diabetic ketoacidosis following l -asparaginase/prednisone therapy in acute lymphoblastic leukemia. Case Reports in Oncological Medicine 2014; article ID 139169, pp 3. doi: 10.1155/2014/139169.
178. TM (collagenase clostridium histolyticum). FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/125338lbl.pdf. Accessed 13 Oct 2014.
179. Hurst LC, Badalamente MA, Hentz VR, et al. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med. 2009;361:968-79.
180. Gilpin D, Coleman S, Hall S, et al. Injectable collagenase clostridium histolyticum: a new surgical treatment for Dupuytren's disease. J Hand Surg Am. 2010;35:2027-38.
181. Coleman S, Gilpin D, Kaplan FT, et al. Efficacy and safety of concurrent collagenase clostridium histolyticum injections for multiple Dupuytren's contractures. J Hand Surg. 2014;39:57-64.
182. Gelbard M, Lipshultz LI, Tursi J, et al. Phase 2b study of the clinical efficacy and safety of collagenase clostridium histolyticum in patients with Peyronie disease. J Urol. 2012;187:2268-74.
183. Gelbard M, Goldstein I, Hellstrom WJG, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo-controlled phase 3 studies. J Urol. 2013;190:199-207.
184. PrPulmozyme® (dornase alfa) recombinant. http://www.rochecanada.com/fmfiles/re7234008/Research/ClinicalTrialsForms/Products/ConsumerInformation/MonographsandPublicAdvisories/Pulmozyme/Pulmozyme-PM-E.pdf. Accessed 13 Oct 2014.
185. Widemann BC, Balis FM, Murphy RF, et al. Carboxypeptidase-G2, thymidine, and leukovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol. 1997;15:2125-34.
186. Buchen S, Ngampolo D, Melton RG, et al. Carboxypeptidase G2 rescue in cancer patients with methotrexate intoxication and renal failure. Br J Cancer. 2005;92:480-7.
187. Widemann BC, Jayaprakash N, Howard SC, et al. Clinical trial and compassionate use experience with glucarpidase for methotrexate toxicity. J Clin Oncol. 2012;30(Suppl):6530.
188. Voraxaze® (glucarpidase). FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/125327lbl.pdf. Accessed 13 Oct 2014.
189. Rattu MA, Shah N, Lee JM, et al. Glucarpidase (voraxaze), a carboxypeptidase enzyme for methotrexate toxicity. P T. 2013;38:732-44.
190. Jetrea® (ocriplasmin). FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/125422s000lbl.pdf. Accessed 13 Oct 2014.
191. Shah SP, Jeng K, Fine HF, et al. Postmarketing surveillance survey of adverse events of ocriplasmin (Jetrea®). Invest Ophthalmol Vis Sci. 2014;55:E-Abstr 2208.
192. Freund KB, Shah SA, Shah VP. Correlation of transient vision loss with outer retinal disruption following intravitreal ocriplasmin. Eye (Lond). 2013;27:773-4.
193. Tibbetts MD, Reichel E, Witkin AJ. Vision loss after intravitreal ocriplasmin: correlation of spectral-domain optical coherence tomography and electroretinography. JAMA Ophthalmol. 2014;132:487-90. doi: 10.1001/jamaophthalmol.2013.8258.
194. Fahim AT, Khan NW, Johnson MW. Acute panretinal structural and functional abnormalities after intravitreous ocriplasmin injection. JAMA Ophthalmol. 2014;132:484-6. doi: 10.1001/jamaophthalmol.2013.8142.
195. Hershfield M, Mitchell BS. Immunodeficiency diseases caused by adenosiune deaminase deficiency and purine nucleoside phosphorylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill; 2001. p. 2585-625.
196. Hershfield MS. Combined immunodeficiencies due to purine enzyme defects. In: Steim ER, Ochs HD, Winkelstein JA, editors. Immunologic disorders in infants and children. Philadelphia: WB Saunders; 2004. p. 480-504.
197. Marwaha VR, Italia DH, Esper H, et al. Extreme thrombocytosis in response to PEG-ADA: early therapeutic and risk indicators. Clin Pediatr (Phila). 2000;39:183-6.
198. Booth C, Gaspar HB. Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID). Biol Targets Ther. 2009;3:349-58.
199. Gentry WM, Dotson MP, Williams BS, et al. Investigation of pegloticase-associated adverse events from a nationwide reporting system database. Am J Health Syst Pharm. 2014;71:722-7.
200. Becker MA, Baraf HSB, Yood RA, et al. Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis. 2013;72:1469-74.
201. Elitek (rasburicase). FDA: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/103946s5083lbl.pdf. Accessed 14 Oct 2014.
202. Browning LA, Kruse JA. Hemolysis and methemoglobinemia secondary to rasburicase administration. Ann Pharmacother. 2005;39:1932-5.
203. Ng JS, Edwards EM, Egelund TA. Methemoglobinemia induced by rasburicase in a pediatric patient: a case report and literature review. J Oncol Pharm Pract. 2012;18:425-31.
204. Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone - results of a multicenter phase III study. J Clin Oncol. 2010;28:4207-13.
205. Baldo BA, Pham NH. Drug allergy: clinical aspects, diagnosis, mechanisms, structure-activity relationships. New York: Springer; 2013.
206. Deegan PB. Fabry disease, enzyme replacement therapy and the significance of antibody responses. J Inherit Metab Dis. 2012;35:227-43.
207. FDA. Immunogenicity assessment for therapeutic protein products, 2013. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338856.pdf. Accessed 14 Sept 2014.
208. Brooks DA, Kakavanos R, Hopwood JJ. Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends Mol Med. 2003;9:450-3.
209. Linthorst GE, Hollak CE, Donker-Koopman WE, et al. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int. 2004;66:1589-95.
210. Vedder AC, Breunig F, Donker-Koopman WE, et al. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab. 2008;94:319-25.
211. Whybra C, Miebach E, Mengel E, et al. A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease. Genet Med. 2009;11:441-9.
212. Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci. 2008;105:2812-7.
213. Bénichou B, Goyal S, Sung C, et al. A retrospective analysis of the potential impact of IgG antibodies to agalsidase β on efficacy during enzyme replacement therapy for Fabry disease. Mol Genet Metab. 2009;96:4-12.
214. Rombach SM, Aerts JMFG, Poorthuis BJHM, et al. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS One. 2012;7:e47805.
215. Wilcox WR, Linthorst GE, Germain DP, et al. Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry. Mol Genet Metab. 2012;105:443-9.
216. Lipsky PE, Calabrese LH, Kavanaugh A, et al. Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014;16:R60. doi: 10.1186/ar4497.
217. Garay RP, El-Gewely R, Armstrong JK, et al. Antibodies against polethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv. 2012;9:1319-23.
218. Freedman R, Sahhar M, Curnow L, et al. Receiving enzyme replacement therapy for a lysosomal storage disorder: a preliminary exploration of the experiences of young patients and their families. J Genet Couns. 2013;22:517-32.
219. Znidar I, Collins-Histed T, Niemeyer P, et al. The European Gaucher Alliance: a survey of member patient organisations' activities. Healthcare environments and concerns. Orphanet J Rare Dis. 2014;9:134. http://www.ojrd.com/content/9/1/134.